Alzheimer disease (AD) is a progressive neurodegenerative disorder affecting more than 37 million people worldwide and increasing in incidence based on its primary risk factor, advancing age. A growing body of knowledge regarding amyloid and tau neuropathology, genetic and environmental risk modifiers, early and atypical clinical presentations, and the use of symptom-modifying medical and psychosocial therapies is available to aid in the diagnosis and management of patients with AD. Exciting recent advances in neurobiology render the areas of genetic susceptibility, biomarkers for early disease detection and assessment of disease progression, and novel therapeutic strategies to modify the natural history of the disease compelling, but in need of further study before implementation into routine clinical practice is feasible.
INTRODUCTION
Alzheimer disease (AD) is the most common form of dementia in aging adults and is characterized by slowly progressive cognitive and behavioral decline with prominent memory dysfunction occurring early in the clinical course. In 1901, Alois Alzheimer initially described the illness in the clinical case of Auguste D, a 51-year-old woman with cognitive disturbance, disorientation, delusions, aphasia, and behavioral dyscontrol. A postmortem presentation followed in 1906 and revealed the presenile dementia to be associated with striking generalized cortical atrophy and unique neuropathologic changes. In a subsequent 1911 publication, Dr Alzheimer described in histologic detail the now disease-defining neurofibrillary tangles and neuritic plaques observed at autopsy. 1 More than a century later, AD now represents the leading cause of dementia worldwide and a well-known cause of death, disability, and financial burden across cultures. 2 In 2000, 4.5 million people in the United States were estimated to have AD with an associated projection that this number would escalate to 14 million by 2050. The incidence of AD is age related, doubling every 5 years after the age of 65. The prevalence is 30% or higher in populations 85 years of age and older. Disease duration varies widely from 2 to 20 years and influences prevalence rates. 2 
PATHOLOGY
Brains of patients with AD demonstrate neuronal loss and shrinkage of large cortical neurons with synaptic loss. This cell loss results in the generalized cortical atrophy observed in gross tissue specimens with sulcal widening, gyral atrophy, thinning of the cortical ribbon, and compensatory ventricular dilatation observed throughout the brain in late stages of the disease (Figure 1-1) . There may be a selective sparing of the occipital pole and a more obvious dilatation of the temporal horn of the lateral ventricle due to preferential hippocampal and amygdalar atrophy. Synaptic loss at the microscopic level is thought by some investigators to be a critical pathologic change because of its high correlation with dementia severity as assessed by clinical measures.
Histologic hallmarks beyond cell loss include those initially described by Alzheimer and now referred to as senile or neuritic plaques and neurofibrillary tangles ( Figures 1-2 and 1-3 ). Other microscopic pathology observed is granulovacuolar degeneration and amyloid angiopathy. Remarkably, the relationship of these histologic changes to pathogenesis in AD remains theoretical.
Neuritic plaques are silver-staining extracellular structures composed of an amyloid core surrounded by swollen neuritic processes. These plaques contain -amyloid protein (A), a 40-42 amino acid peptide that is derived from the proteolytic cleavage of the large transmembrane amyloid precursor protein (APP). 3 A was initially thought to be an abnormal protein, although subsequent evidence suggests that A is produced during normal cell metabolism via the action of two proteases, -secretase and -secretase. Neuritic plaque burden was previously thought to correlate with AD severity, but more recently pathologic changes have been hypothesized by some investigators to be referable to an imbalance in production and clearance of A, particularly the more toxic, fibrillogenic form, A . Decreased clearance of toxic A isoforms is implicated in sporadic AD, whereas increased production is implicated in familial AD.
Neurofibrillary tangles (NFTs) are intraneuronal cytoplasmic inclusions composed of hyperphosphorylated tau, a normal axonal protein associated with microtubule binding and stabilization. 4 Ubiquitin and neurofilament protein make less prominent contributions to tangle formation. Similar to neuritic plaques, NFTs represent an abnormal process of aggregation. Selective vulnerability to this neuropathology is evidenced by a predictable distribution of NFTs beginning in the transentorhinal cortex with subsequent spread to the hippocampus, amygdalar regions, and neocortex. The evolution of NFT pathology appears to be independent of plaque formation. Unlike amyloid plaque burden, NFT formation appears to correlate well with specific deficits such as memory loss. The exact relationship of both neuropathologic signatures of AD to disease onset and progression remains to be further elucidated. 5 In association with the aforementioned cellular changes, cell loss in the nucleus basalis of Meynert, the basal forebrain structure responsible for most cortical cholinergic projections, results in depletion of cortical acetylcholine, the most notable neurochemical alteration associated with AD. Neurochemical deficiencies in dopamine, norepinephrine, and serotonin have also been detected in postmortem AD brains.
GENETICS
Age remains the primary risk factor for the development of AD. However, while AD is considered an illness of advanced age, recent evidence suggests that earlylife exposures may influence the clinical expression of the illness. 6 In fact, genetic factors may be the earliest influences on risk for AD and may begin expression in utero, thus rendering family history the second greatest risk factor for the development of AD. A heritability study showed that as much as 80% of the variability in AD is related to genetic factors whereas 20% appears related to environmental contributions. 7 Whereas the etiology of about 75% of AD is unknown, possibly due to a combination of genetic and environmental factors, about 25% is clearly familial, with two or more family members affected with AD. For familial AD, about 95% of AD is late onset, occurring after age 60 to 65, and approximately 5% is early onset, occurring before age 60 to 65, with some cases occurring as early as the thirties. 8 Among early-onset AD, 60% of cases are familial and 40% appear to be sporadic. Only 10% to 15% of all early-onset cases (and less than 2% of all AD cases) appear to be due to autosomal dominant transmission. 8 The three genes identified with autosomal dominant mutations causing early-onset familial AD (EOFAD) include: (1) APP on chromosome 21, (2) presenilin 1 (PSEN1) on chromosome 14, and (3) presenilin 2 (PSEN2) on chromosome 1. Of these three mutations, PSEN1 is the most common, accounting for as much as 70% of EOFAD. Mutations in APP are the next most common and account for 10% to 15% of EOFAD, whereas mutations in PSEN2 are very rare (less than 5%). These genes share a common biochemical pathway that leads to abnormal production of amyloidBoth PSENs are highly homologous and are thought to play a role in amyloid production via the -secretase cleavage system. APP is cleaved byand -secretase into the A peptide, the principal component of AD amyloid (2) plaques. Commercial testing is available for all three genes, although if no family history is present, the chance of finding a mutation in PSN1 is less than 5%. 8 Comprehensive websites detailing the identified mutations can be found at www.alzforum.org and www.molgen. ua.ac.be/ADMutations.
The allelic variant of apolipoprotein E (APOE), "4, found on chromosome 19 is the genetic factor that has been most strongly associated with both late-onset familial and sporadic AD. ApoE plays an important role in cholesterol transport, but the exact mechanism by which it promotes disease at the molecular level remains uncertain. Some studies suggest the "4 allele influences where A aggregates and affects its conformation and toxicity. 8, 9 The proportion of AD estimated to be related to the APOE "4 allele is nearly 20%. A single APOE "4 allele increases the risk of acquiring twofold to threefold, whereas two APOE "4 alleles (a homozygous genotype) increases the risk by a factor of five to 15.
2,10 It appears that the APOE "4 allele modifies the age of illness onset in sporadic and late-onset familial AD by shifting it approximately 10 years earlier per allelic copy. Other genes, such as SORL1 (see below), are also implicated in late-onset familial AD. 8 Commercial testing for APOE genotyping is available but not recommended in routine clinical practice for diagnostic or predictive testing as APOE "4 is neither necessary nor sufficient to cause AD and has not been proven to increase diagnostic certainty (Table 1-1) . Physicians should also be aware that direct-toconsumer testing is currently available for APOE, and it is likely that some individuals will pursue this option without first seeking medical advice or appropriate counseling. 11 If persons pursue this or other AD genetic testing, then it is most appropriate to follow the guidelines established for Huntington disease, another adult-onset neurodegenerative disease with no currently available disease-modifying therapies. 12 Using advancing genetic technology, researchers have recently embarked on both candidate gene-based studies and genome-wide and chromosome-wide linkage/association studies to identify other AD susceptibility genes. 13 For example, using the candidate gene-based approach, applying converging evidence from inherited forms of AD and neuropathologic studies, investigators have recently described an association between AD and variation in the neuronal sortilinrelated receptor (SORL1) in families with late-onset AD. SORL1 is known to be involved in the processing of APP and also functions as a lipoprotein receptor, although the exact mechanism of its contribution to the development of AD remains to be more clearly defined. Unlike APOE "4, no single SORL1 haplotype has been implicated in the development of AD, but the gene, found on chromosome 11, was associated with disease development in several unique data sets. Chromosome-wide association studies have focused on chromosomes 9, 10, and 12, although replication of large linkage and association peaks has proven difficult. Examples of genes that have been identified via large association studies with findings confirmed in independent samples include the 
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OTHER RISK MODIFIERS
Risk modifiers for clinical expression of the disease from early life may include head circumference in the first decade of life, general body growth continuing through the second decade of life, and socioeconomic status as it relates to environmental enrichment and nutritional status. 15 Additional early to midlife potential contributors to AD neuropathologic changes include head injury, obesity, insulin resistance, 16 and other identifiable vascular risk factors, including hypertension, hyperlipidemia, and obstructive sleep apnea. 17 When considering risk factors for AD, it may be important to separate risk factors that predict neuropathologic changes characteristic of the disease from those that predict risk for clinical expression of AD. 6 This approach reflects current hypotheses of ''cognitive reserve,'' the seemingly protective effect of increasing formal education in delaying the onset of AD symptoms in spite of concomitant neuropathologic changes consistent with the diagnosis of AD. 18 Although initially presumed to reflect a bias in neuropsychological screening tests, prospective cohort studies have confirmed the association between a higher risk of developing AD in subjects with lower educational attainment. Moreover, it has been observed that subjects with a higher number of years of formal education may decline more rapidly following the diagnosis of probable AD.
Environmental risk modifiers in midlife have also been considered in epidemiologic studies, suggesting that regional variability in diet and exercise may significantly influence the risk of the development of AD. Modest to moderate intake of alcohol has been suggested to lower the risk of AD 2, 19 while moderate intake of saturated fats may increase the risk for developing AD. 20 Likewise, a diet high in unsaturated fat, fish, vegetables, fruits, and legumes has been associated with a reduction in AD risk. While associations of high intake of vitamins C, E, B 6 , B 12 , and folate with a lower risk of developing AD have been reported, interventional study results have been inconsistent.
Physical exercise in midlife has also been associated with a reduced risk for the development of AD independent of other risk factors in both epidemiologic studies and prospective randomized trials. 21 Theoretically, ''cognitive exercise'' should also reduce the risk for developing AD, and while this evidence has been difficult to dissociate from preintervention education, IQ, and other environmental confounds, a recent metaanalysis demonstrates benefit in patients with AD. 22 Social activities appear to be equally important, as middle-aged individuals with isolated lifestyles are more apt to develop cognitive decline with aging. 23 Late-life depression may also be a risk factor for dementia, although conflicting population-based studies also suggest depression as a possible prodromal state to AD. In either case, the two conditions are clearly linked, and late-life depression warrants an investigation of cognitive function (Case 1-1 CLINICAL HISTORY AND NEUROLOGIC EXAMINATION Obtaining a detailed history from the patient and a well-acquainted informant is of primary importance in diagnosing AD. The most common presenting symptom in AD is insidious episodic memory impairment, often involving names of persons or objects. These concerns reflect AD pathology in the neuroanatomically vulnerable basal forebrain and medial temporal structures. Later clinical features, including visuospatial dysfunction and language deterioration, reflect the characteristic spread of pathology to involve the posterior cingulate gyrus and the isocortex of the temporal and parietal lobes. 5, 25 Visuospatial deficits are often recognized when patients become lost or A 60-year-old high-functioning CEO of a large company presented without an informant and without specific cognitive concerns. He was preparing for a planned early retirement and attempting to educate himself about AD. His mother began to have difficulty recollecting names in her late sixties and by age 72 required full assistance for her activities of daily living. She was diagnosed with probable AD and died at age 74 as a consequence of bronchopneumonia. Near the time of her death two of her younger sisters began to develop memory difficulties in their late sixties, and while one sister lived into her eighties, both required placement in an extended care facility several years after the onset of their symptoms. There was no other family history of neurodegenerative or neuropsychiatric illness in preceding or subsequent generations.
The CEO's review of cognitive domains was negative, and he denied any changes in motor, sleep, and autonomic function. He had recently received a diagnosis of mild hypertension from his primary care physician and had started taking a low-dose beta-blocker. He otherwise had no past medical history and took no other medications. He had graduated at the top of his MBA class and remained active playing tennis and golf. He had never been a tobacco smoker and drank wine socially, about two to three glasses per week. His general physical and neurologic examinations, including neurobehavioral status examination, were normal.
Comment. Ideally, an informant would be available to provide a collateral history for all patients who present for cognitive evaluation or counseling regarding dementia diagnoses. However, based on the preceding interaction, this patient was presumed to have normal cognition with a family history of probable AD in multiple members of a single generation. One approach to coordination of care for this patient would be to refer him to a local observational research program where he could undergo baseline neuropsychological testing and possibly enroll in a research neuroimaging protocol. Neither of these investigations is clinically indicated given his lack of signs or symptoms. Likewise, predictive genetic testing is not recommended in this scenario.
Counseling would be aimed at reducing vascular risk factors and other presumed risk modifiers for AD with continued engagement in daily exercise and social activities. Cognitive exercise, particularly something novel and enjoyable to him, may also be beneficial. A diet low in saturated fats with an emphasis on whole grains and fish and one glass of red wine per day may be recommended.
KEY POINT
" ALZHEIMER DISEASE UPDATE disoriented while navigating. Misplacement of personal objects, such as glasses or keys, with increasing frequency may also reveal a visual memory deficit. As a consequence of the involvement of the temporal and parietal lobes with disease advancement, the ventral what and dorsal where visual pathways both may be disrupted by AD, although the occipitotemporal network appears to be more vulnerable. Reduced spontaneous verbal output often accompanies early memory symptoms, but many patients develop other language deficits, including anomia and nonfluency with prominent word-finding problems, hesitancy, and occasional paraphasic errors. Grammar and syntax may also become progressively less complex. 26, 27 Other cognitive symptoms, such as executive dysfunction (difficulty planning, sequencing, or abstracting), agnosia (difficulty recognizing objects), and apraxia (inability to perform a learned motor act), occur with variable frequency in patients with AD, most often in the moderate to late stages of the illness. Neuropsychiatric symptoms are reported in up to 80% of patients with AD, 27 with depression, apathy, and agitation most commonly noted by caregivers. Anxiety and delusions, often paranoid, become more common as the illness progresses.
The general neurologic examination is typically unremarkable in mild to moderate AD. Later in the illness patients may develop pyramidal signs with hyperreflexia or extrapyramidal parkinsonism, although these findings may be referable to concomitant vascular or Lewy body pathology. Dysphagia is an important late symptom of the disease and is likely a contributing factor to most AD deaths resulting from bronchopneumonia.
Bedside mental status testing is critical for confirming the domains of cognitive deficit elicited during the neurologic 31 These guidelines, currently undergoing modification, recommend screening for depression, hypothyroidism, and vitamin B 12 deficiency as potentially treatable causes of cognitive impairment, as well as neuroimaging as part of an initial evaluation for possible dementia. Structural neuroimaging with MRI or noncontrast CT scan allows the clinician to assess for structural pathology, including neoplasms, cerebrovascular lesions, and hydrocephalus, while confirming the typical changes associated with AD.
Several other laboratory tests may be recommended, depending on the clinical scenario. In a departure from prior recommendations, syphilis screening now is recommended by the AAN only in the context of a clinical suspicion of neurosyphilis. EEG is not recommended for routine use in the diagnosis of dementia and is often normal in AD; EEG, however, may be useful in distinguishing dementia from delirium or depression and for diagnosing seizures, which may accompany AD pathology in up to 17% of cases and may be present at the time of diagnosis in up to 6% of cases. Of interest, recent research suggests that tau levels might affect cognition and be involved in subclinical seizures in an AD mouse model. 32 At present, CSF studies are not recommended by the AAN for routine use in the clinical evaluation of patients with suspected AD. However, in certain scenarios CSF studies may help differentiate AD from inflammatory, infectious, or neoplastic causes of cognitive dysfunction.
CSF AND SERUM INVESTIGATIONAL BIOMARKERS
Potential diagnostic biomarkers of AD are subject to expert consensus criteria that specify the need for sensitivity approaching 85% and specificity of 75% in the context of validation in patients with neuropathologic confirmation of disease. Investigational biomarkers have yet to meet these stringent ''ideal'' criteria and gain wide acceptance in clinical practice 33 ; however, several CSF and serum targets show promise across monocenter trials and large cooperative studies such as the Alzheimer's Disease Neuroimaging Initiative (www.adniinfo.org). 34 Reduction in the CSFamyloid and mild to moderate elevation in the CSF tau protein combined yield a reported sensitivity and specificity of approximately 80% to 90% in comparing patients with AD and controls, although some overlap with other syndromes occurs. This overlap may be reduced with the use of assays for both total tau and phosphorylated tau, with high levels of phosphorylated tau increasing diagnostic specificity for AD. These CSF biomarkers may also accurately predict incipient AD in patients
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Case 1-2
A 70-year-old woman presented for evaluation in the company of her daughter who lived in another city. The patient's daughter spoke to her several times per week via telephone and was concerned with a decline in her mother's memory over the past 3 years. The patient stated simply, ''I forget names really bad, but I'm 70.'' Specific examples included increasing repetition of conversations via telephone and missed medication doses. Although she had no visual hallucinations, the patient believed that someone had been coming into her home and moving her personal items in order to frustrate her. She had neither developed difficulty navigating around her town nor become involved in automobile accidents. Functionally, she denied difficulty planning daily activities, but her daughter could not confirm this. Behaviorally, the patient described her mood as ''just fine.'' Her daughter found her more irritable and agitated.
Her past medical history included hypothyroidism and hyperlipidemia. She was a high school graduate who had worked as a cook. She had been living independently for 25 years following her spouse's death. She had no family history of neuropsychiatric illness.
General and neurologic examinations were unremarkable. On neurobehavioral status examination, the patient was reticent and frustrated. No obvious speech, language, or praxis deficits were present. On screening Mini-Mental Status Examination, the patient scored 21/30. On a test of verbal memory, the patient was able to learn 5/9 words after four trials, and after a 10-minute delay, she recalled 0/9 words. She also demonstrated poor figure recall, impaired digit span backward (suggesting poor working memory), and an inability to complete a set-shifting task.
Screening thyroid function studies and serum vitamin B 12 were normal. Brain MRI demonstrated scattered T2 hyperintensities consistent with small vessel ischemic changes and bilateral hippocampal atrophy with compensatory dilatation of the temporal horns of the lateral ventricles.
Comment. This patient has mild to moderate, probable AD based on the available clinical history, neurobehavioral testing, and imaging data, although vascular disease might be another contributing factor to her dementia. She began treatment with a cholinesterase inhibitor, with plans to consider the addition of memantine in the future. Her family was advised of the risks and benefits of low-dose, newer generation antipsychotics if needed for the delusional behavior. She was encouraged to refrain from driving, and an independent driving evaluation was arranged. The family was counseled regarding the need for additional supervision in the home and planning for future interventions (financial, medical, etc) given the progressive nature of AD.
KEY POINTS
Continuum Lifelong Learning Neurol 2010;16 (2) with mild cognitive impairment (MCI). Additional predictive utility of CSF biomarkers has been suggested by one investigation that demonstrated that CSF -amyloid 1-42 deficits correlated with earlier death while increased CSF tau levels may correlate with dementia severity. 35 More recent data suggest that low A42 levels, as well as the ratio of phosphorylated tau to A42, in CSF have high predictive value for AD diagnosis 36 and AD pathology. 37 Some clinicians argue that these CSF markers may be as useful as the amyloid PET imaging agent Pittsburgh compound B (PiB) (discussed later in this chapter) for AD diagnosis.
Attempts to identify similar biomarkers for AD in serum, plasma, and peripheral blood have yielded contradictory results, with major efforts focused on quantification of A species. Serum results have not demonstrated a consistent relationship with either CSF A or microscopic brain accumulation of amyloid. Investigators using an unconventional approach have recently identified a ''biochemical signature'' of AD, composed of 18 signaling proteins, after investigating samples from AD, other dementias, other inflammatory conditions, MCI, and controls. The protein signature not only differentiated AD from controls and other conditions, but also predicted conversion from MCI to AD in 20 of 22 subjects. This technique will require further validation in a larger and broader population before consideration of use in clinical diagnosis; however, the relative ease of obtaining plasma samples is alluring. 38 
NEUROIMAGING BIOMARKERS
Structural MRI and CT in AD most often demonstrate nonspecific, generalized atrophy with more pronounced atrophy in the medial temporal structures. 26 As expected, based on the known distribution of neuropathologic change in AD, " ALZHEIMER DISEASE UPDATE the hippocampus and entorhinal cortex are subject to relatively greater atrophy when studied with volumetric measures. Unfortunately, this pattern is sensitive, but not specific, for AD, confounded by considerable overlap with other dementia subtypes and normal aging. Other imaging techniques, including functional imaging with [ TREATMENT STRATEGIES Based on the known neurochemical derangements in AD, two classes of medication have been approved for treatment of cognitive symptoms in the United States: (1) cholinesterase inhibitors, including donepezil, galantamine, and rivastigmine, and (2) an NMDA receptor antagonist, memantine. These agents have demonstrated modest effects for 2 to 5 years on measures of cognition, activities of daily living, and global function versus placebo in a number of randomized, double-blind trials. 39 Slight pharmacodynamic differences can be found in the three cholinesterase inhibitors, and rivastigmine has recently been introduced in a transdermal formulation to decrease gastrointestinal side effects compared to the oral form, although no evidence suggests that the agents differ in efficacy. Medication side effects may be limited with a gradual titration to the recommended dosage and are generally mild. Reported clinical concerns include gastrointestinal symptoms, insomnia or vivid dreams, leg cramps, and symptomatic bradycardia. The latter may prompt a baseline EKG before initiation of cholinesterase inhibition in a patient with cardiovascular risk factors. The US Food and Drug Administration (FDA) has approved all cholinesterase inhibitors for the treatment of mild to moderate AD with an indication for severe AD granted to donepezil. These medications are recommended as standard therapy for AD by the AAN. 40 Memantine is a noncompetitive NMDA receptor antagonist theorized to protect neurons from excitotoxicity associated with glutamatergic activity. Its precise mechanism of action in AD is not clearly defined; however, the glutamate transporter is known to be downregulated in AD, leading to changes in amyloid-and tau burden. Clinical trials of memantine in AD suggest improvement on measures of cognition, behavior, and activities of daily living in moderate to severe AD with an added benefit when used in combination with cholinesterase inhibition. The medication side effect profile was similar to placebo in randomized studies. 41 Memantine is currently approved by the FDA for use in moderate to severe AD ( Table 1-4) .
Adequately managing behavioral signs and symptoms in AD remains a considerable challenge for caregivers. Depression is common in AD, and several placebocontrolled treatment trials have demonstrated mixed results with both tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs). Because of the anticholinergic side effect profile of TCAs, SSRIs serve as the firstline option for most clinicians. Anxiety often manifests as a fear of being left unattended in patients with AD, with anecdotal evidence suggesting that SSRIs may be a useful tool in managing this symptom. The cognitive side effect profile of the more commonly prescribed anxiolytic benzodiazepines is relatively unattractive in this patient population. 42 Sleep disturbance may also respond to specific antidepressant medications such as mirtazapine. 27 Psychotic symptoms associated with AD include hallucinations, delusions, agitation, and aggression, although these typically occur late in the course. It is important to rule out delirium prior to the initiation of pharmacotherapy to treat psychotic symptoms. Most clinicians would opt for newer generation antipsychotic medications, although this practice is not approved by the FDA, with a recent black box warning label requirement on such medications, because of the suggestion of increased mortality. 43 Fortunately, neuropsychiatric symptoms may respond to initiation of cholinesterase inhibition, memantine, or a combination of these AD medications.
25
Nonpharmacologic interventions, which emphasize patient and caregiver safety, are paramount in AD. One issue that may dramatically change the lifestyle of a patient with AD is revocation of driving privileges. Current physician reporting standards in the United States vary by state. The AAN recommends that patients with a functional measure signifying mild dementia with memory predominance be advised to discontinue driving. 44 (The 2000 AAN practice parameter on risk of driving and Alzheimer disease is currently being updated). Whereas current predictors of driver fitness may be inadequate and warrant further study, the up to eightfold increase in collisions involving driving by patients with AD must be addressed.
INVESTIGATIONAL THERAPEUTICS
Currently available interventions improve symptoms associated with AD, but strategies to halt disease progression or prevent disease development are the major candidates for affecting change in the natural history and epidemiology of AD. Therapeutic targets for disease modification include both A and tau, as well as other aspects of AD dysfunction ( Table 1-5) . 45 Further therapeutic interventions currently under investigation are largely based on observational data, which is often difficult to reproduce with a welldesigned prospective study. For example, anti-inflammatory agents have been recognized to reduce the risk of AD in epidemiologic studies; yet, both steroids and nonsteroidal anti-inflammatory drugs have demonstrated no effect on cognitive outcomes in AD clinical trials. Estrogen replacement therapy in postmenopausal women was also associated with reduced risk for AD in epidemiologic studies, although clinical trials have not supported the use of estrogen for AD risk reduction. Similarly, case-control data of statin use in large prospective cohorts suggest that these lipid-lowering agents may modify risk for AD development, although clinical trials for use in diagnosed AD have been consistently negative. A recent randomized controlled trial using the naturopathic agent ginkgo biloba over a 6-year period was equally disappointing as it failed to demonstrate a significant difference in incident AD in treated subjects.
In spite of the growing body of knowledge regarding AD, the diagnosis and treatment of patients with AD need improvement. In primary care settings, fewer than 50% of patients with dementia are diagnosed 46 with a consequential lack of screening for potentially treatable conditions. Equally surprising, only half of patients currently diagnosed with AD are treated with currently approved therapies. 27 While several recent phase 3 clinical trials of potentially diseasemodifying agents such as tarenflurbil, phenserine, tamiprostate, and xaliproden have yielded negative results, interventions including latrepirdine, IV immunoglobulin, and methylthioninium continue to generate excitement for altering the deadly progression of AD pathology. 47 With such exciting new treatments already in clinical trials, 45 it is important to advocate for accurate and early diagnosis or referral to dementia specialists, as well as appropriate symptom management with approved medications and efficacious yet conservative 27 (2) interventions such as exercise. New biomarker technologies and multicenter cooperative investigational efforts offer a glimpse of an exciting future when a successful preventive strategy for AD will be readily accessible for patients.
